Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.33 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.33 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | KDM6B | O15054 | 1/20 | 0.32 |
| ▸ | KDM5C | P41229 | 1/20 | 0.32 |
| ▸ | CTH | P32929 | 1/20 | 0.31 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.30 |
| ▸ | ACLY | P53396 | 2/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16057049 | 0.97 | EGLN1 (0.32) | EGLN1LMNALDHASRRALKBH5 | |
| SCHEMBL18509319 | 0.80 | CTH (0.38) | EGLN1LMNALDHASRRPHF8 | |
| SCHEMBL23553761 | 0.80 | CTH (0.33) | EGLN1LMNALDHASRRALKBH5 | |
| SCHEMBL20377964 | 0.80 | LDHA (0.30) | EGLN1LMNALDHASRRALKBH5 | |
| SCHEMBL22716360 | 0.80 | LMNA (0.36) | EGLN1LMNAALKBH5SUCNR1SMN1; SMN2 | |
| SCHEMBL23586903 | 0.78 | CA1 (0.31) | — | |
| SCHEMBL2882844 | 0.77 | — | — | |
| SCHEMBL1376701 | 0.77 | MAOA (0.40) | — | |
| SCHEMBL19844616 | 0.77 | KDM4E (0.31) | EGLN1PHF8KDM2AKDM4EKDM6B | |
| SCHEMBL28818283 | 0.77 | LMNA (0.42) | LMNASLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4805909-B2 | — | — | 2011-11-02 | — | — | JP | claimed |
| EP-1725522-A1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-29 | — | — | EP | claimed |
| WO-2005085185-A1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-15 | — | — | WO | claimed |
| US-20250269046-A1 | CELLULAR UPTAKE OF LARGE BIOMOLECULES ENABLED BY CELL-SURFACE-REACTIVE CELL-PENETRATING PEPTIDE ADDITIVES | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2025-08-28 | — | — | US | disclosed |
| US-20240083857-A1 | 2-Methyl-Quinazolines | Bayer Pharma AG (DE) | 2024-03-14 | — | — | US | disclosed |
| EP-4297794-A2 | CELLULAR UPTAKE OF LARGE BIOMOLECULES ENABLED BY CELL-SURFACE-REACTIVE CELL-PENETRATING PEPTIDE ADDITIVES | Forschungsverbund Berlin E.V. (DE) | 2024-01-03 | — | — | EP | disclosed |
| EP-4092038-A1 | OPIOID AGONIST PEPTIDES AND USES THEREOF | Protagonist Therapeutics, Inc. (US) | 2022-11-23 | — | — | EP | disclosed |
| WO-2022180242-A2 | CELLULAR UPTAKE OF LARGE BIOMOLECULES ENABLED BY CELL-SURFACE-REACTIVE CELL-PENETRATING PEPTIDE ADDITIVES | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2022-09-01 | — | — | WO | disclosed |
| US-20220235013-A1 | 2-METHYL-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-07-28 | — | — | US | disclosed |
| CN-113395982-A | Insulin conjugates | 赛诺菲 | 2021-09-14 | — | — | CN | disclosed |
| CN-113396157-A | Insulin analogs with reduced insulin receptor binding affinity | 赛诺菲 | 2021-09-14 | — | — | CN | disclosed |
| WO-2011097421-A1 | MULTIPLE SUBSTITUTED FLUOROMETHANES AS SELECTIVE AND BIOACTIVE ISOSTERES | MEH ASSOCIATES, INC (US) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011097421-A1 | MULTIPLE SUBSTITUTED FLUOROMETHANES AS SELECTIVE AND BIOACTIVE ISOSTERES | MEH ASSOCIATES, INC (US) | 2011-08-11 | — | — | WO | disclosed |
| EP-2309850-A2 | SURFACE-IMMOBILIZED ANTIMICROBIAL PEPTOIDS | Northwestern University (US) | 2011-04-20 | — | — | EP | disclosed |
| EP-2283030-A1 | PEPSTATIN A DERIVATIVES | Freie Universität Berlin (DE) | 2011-02-16 | — | — | EP | disclosed |
| WO-2010014940-A2 | SURFACE-IMMOBILIZED ANTIMICROBIAL PEPTOIDS | NORTHWESTERN UNIVERSITY (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20100028719-A1 | Surface-Immobilized Antimicrobial Peptoids | NORTHWESTERN UNIVERSITY | 2010-02-04 | — | — | US | disclosed |
| WO-2009133188-A1 | PEPSTATIN A DERIVATIVES | FREIE UNIVERSITÄT BERLIN (DE) | 2009-11-05 | — | — | WO | disclosed |
| CN-101180266-A | Alpha ketoamide compounds as cysteine protease inhibitors | APPLERA CORP (US) | 2008-05-14 | — | — | CN | disclosed |
| US-6428951-B1 | COMPRISING REASSEMBLY OF SEPARATE FRAGMENTS OF MONOMERIC ENZYME WHEREIN REASSEMBLY OF MONOMERIC ENZYME FRAGMENTS IS OPERATED BY INTERACTION OF MOLECULAR DOMAINS FUSED TO EACH MONOMERIC ENZYME FRAGMENT | ODYSSEY PHARMACEUTICALS, INC. | 2002-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083857-A1 | 2-Methyl-Quinazolines | NRAS, KRAS, KSR2 | EGLN1 2028/4885LMNA 3538/4885LDHA 4857/4885 |
| US-20250269046-A1 | CELLULAR UPTAKE OF LARGE BIOMOLECULES ENABLED BY CELL-SURFACE-REACTIVE CELL-PENETRATING PEPTIDE ADDITIVES | GZMB, SLC7A5, SLC7A1 | EGLN1 4263/4885LMNA 1034/4885LDHA 771/4885 |
| US-20220235013-A1 | 2-METHYL-QUINAZOLINES | NRAS, KRAS, KSR2 | EGLN1 2028/4885LMNA 3538/4885LDHA 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.